Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. WuXi Biologics (Cayman) Inc.
  6. News
  7. Summary
    2269   KYG970081173

WUXI BIOLOGICS (CAYMAN) INC.

(2269)
  Report
End-of-day quote. End-of-day quote Hong Kong Stock Exchange - 09/16
116.4 HKD   -0.85%
09/14Hong Kong shares end lower, dragged by property, financials and tech
RE
09/06Hong Kong shares rise, led by tech and financials
RE
09/01Hong Kong shares rise as tech, financial sectors gain
RE
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Wuxi Biologics Receives Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility

07/26/2021 | 06:00am EDT

WuXi Biologics (Cayman) Inc. announced that it has received the License of Manufacturing Permit from German health authorities for its drug product facility (DP7) in Leverkusen, Germany. The permit successfully demonstrates for the first time that Premier Quality together with Record Speed WuXi Biologics consistently delivered in China can also be applied in global countries. The six-day inspection was conducted by five inspectors from the Health Authority of Cologne District Government (Bezirksregierung Köln) and other regional inspectorates. The scope of the inspections comprised not only the areas of cGMP manufacturing required for receiving the permit, but also commercial production approval. The inspection covered quality systems, documents and training, facilities, utilities and equipment qualifications, aseptic DP production, material and supplier management, QC Labs, as well as electronic systems and data integrity. The facility is slated to begin commercial manufacturing of a key product next week.


© S&P Capital IQ 2021
All news about WUXI BIOLOGICS (CAYMAN) INC.
09/14Hong Kong shares end lower, dragged by property, financials and tech
RE
09/06Hong Kong shares rise, led by tech and financials
RE
09/01Hong Kong shares rise as tech, financial sectors gain
RE
09/01WuXi Biologics Received First Manufacturing License from Japan and Completed ..
CI
09/01China stocks gain as policy easing expectations rise; Hong Kong up
RE
08/24WUXI BIOLOGICS CAYMAN : Voluntary announcement - appointment of co-chief financi..
PU
08/24Wuxi Biologics Inc. Appoints Ming Tu as Executive Vice President
CI
08/24WuXi Biologics Inc. Announces Appointment of Ming Tu as Co-Chief Financial Of..
CI
08/24HK stocks rise the most in 3 weeks as bargain hunters snap up tech shares
RE
08/24China shares rise as new energy, liquor sectors gain
RE
More news
Analyst Recommendations on WUXI BIOLOGICS (CAYMAN) INC.
More recommendations
Financials
Sales 2021 9 581 M 1 484 M 1 484 M
Net income 2021 2 987 M 463 M 463 M
Net cash 2021 5 873 M 910 M 910 M
P/E ratio 2021 163x
Yield 2021 -
Capitalization 494 B 63 410 M 76 441 M
EV / Sales 2021 50,9x
EV / Sales 2022 34,5x
Nbr of Employees 7 686
Free-Float 84,3%
Chart WUXI BIOLOGICS (CAYMAN) INC.
Duration : Period :
WuXi Biologics (Cayman) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WUXI BIOLOGICS (CAYMAN) INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 116,40 CNY
Average target price 130,08 CNY
Spread / Average Target 11,8%
EPS Revisions
Managers and Directors
Zhi Sheng Chen Chief Executive Officer & Executive Director
Shao Hua Lu-Wong Co-Chief Financial Officer
Ming Tu Co-Chief Financial Officer & Executive VP
Ge Li Non-Executive Chairman
Weichang Zhou Executive Director, Chief Technology Officer & EVP
Sector and Competitors